Tonix Pharmaceuticals Announces Poster Presentation at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 13 2024
0mins
Should l Buy ?
Source: Globenewswire
Presentation Announcement: Tonix Pharmaceuticals will present a poster on their Phase 3 trial of TNX-102 SL for fibromyalgia at the ACR Convergence 2024 Annual Meeting in Washington, D.C., on November 17, 2024.
Company Overview: Tonix Pharmaceuticals is focused on developing therapies for pain management and CNS disorders, with several investigational products in its pipeline, including TNX-102 SL for fibromyalgia and other candidates targeting various health challenges.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
